5-HMF通过调节GluR2来改善线粒体功能和促进血管生成,在缺血性中风中发挥干预作用
Yan Zhang1, Peipei Yuan1,2, Yaxin Wei1
1Henan University of Chinese Medicine, Zhengzhou, 450046, China.
Biochemistry and biophysics reports
|September 10, 2025
概括
5-基甲 (5-HMF) 通过改善神经功能和保护大脑细胞,有望预防缺血性中风. 这种化合物调节GluR2表达并增强线粒体功能,提供一种潜在的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 5-氧甲基 (5-HMF) 具有各种药理作用,包括抗氧化和抗炎性质.
- 缺血性中风仍然是导致残疾的主要原因,需要新的治疗干预措施.
研究的目的:
- 研究5-HMF对缺血性中风的预防作用.
- 在缺血性中风模型中阐明5-HMF作用的潜在机制.
主要方法:
- 中脑动脉封闭 (MCAO) 鼠标模型被用于评估行为,神经和线粒体功能.
- 诱导人脑微血管内皮细胞 (HBMECs) 的氧气-葡萄糖剥夺-重氧化 (OGD-R) 模型被用于评估细胞和线粒体对5-HMF的反应,有或没有GluR2沉默.
主要成果:
- 在MCAO大鼠中,5-HMF显著改善了行为结果,神经功能,并减少了脑梗塞.
- 在体外,5-HMF增强了HBMEC活力,增加了GluR2表达,并改善了线粒体功能,GluR2沉默的效果被逆转.
- 5-HMF通过降低亡,ROS和Ca2+水平来显示神经保护作用,同时增加线粒体膜潜力.
结论:
- 5-HMF改善了MCAO诱导的缺血性中风中的大脑损伤.
- 保护机制包括调节GluR2表达,降低细胞内Ca2+度,改善线粒体功能,促进血管生成.
更多相关视频
08:53Assessing Neuroprotective Effects of Glycyrrhizae Radix et Rhizoma Extract Using a Transient Middle Cerebral Artery Occlusion Mouse Model
Published on: December 9, 2018
7.7K
06:54A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
Published on: June 22, 2022
3.2K
相关概念视频
Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Regulation of Hematopoietic Stem Cells
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Introduction to Fibroblasts
Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
Role of Hematopoietic Growth Factors
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
